SG11201804674UA - Heteroarylhydroxypyrimidinones as agonists of the apj receptor - Google Patents
Heteroarylhydroxypyrimidinones as agonists of the apj receptorInfo
- Publication number
- SG11201804674UA SG11201804674UA SG11201804674UA SG11201804674UA SG11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA SG 11201804674U A SG11201804674U A SG 11201804674UA
- Authority
- SG
- Singapore
- Prior art keywords
- pennington
- bristol
- new jersey
- international
- myers
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 1111111111111111111111111111111111111111111111111111111111111111111111111111R111111111111111 (10) International Publication Number WO 2017/106396 Al WIPO I PCT (43) International Publication Date 22 June 2017 (22.06.2017) (51) International Patent Classification: pany, 311 Pennington Rocky Hill Road, Pennington, New C07D 413/14 (2006.01) C07D 417/14 (2006.01) Jersey 08534 (US). PI, Zulan; c/o Bristol-Myers Squibb C07D 403/04 (2006.01) A61K 31/513 (2006.01) Company, 311 Pennington Rocky Hill Road, Pennington, C07D 413/04 (2006.01) A61P 9/00 (2006.01) New Jersey 08534 (US). BRIGANCE, Robert Paul; 28 (21) International Application Number: PCT/US2016/066750 nington Rocky Hill Road, Pennington, New Jersey 08534 Lakeside Drive, Levittown, PA 19054 (US). FINLAY, Heather; c/o Bristol-Myers Squibb Company, 311 Pen- (US). (22) International Filing Date: 15 December 2016 (15.12.2016) et al.; Bristol-Myers (74) Agents: JACOBSEN, Barry H. Squibb Company, Route 206 and Province Line Road, English (25) Filing Language: Princeton, New Jersey 08543 (US). English (26) Publication Language: (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/267,997 16 December 2015 (16.12.2015) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, [US/US]; Route 206 and Province Line Road, Princeton, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, New Jersey 08543 (US). KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (72) Inventors: MYERS, Michael C.; c/o Bristol-Myers MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Squibb Company, 311 Pennington Rocky Hill Road, Pen- NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, nington, New Jersey 08534 (US). LAWRENCE, R. Mi- RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, chael; c/o Bristol-Myers Squibb Company, 311 Penning- TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ton Rocky Hill Road, Pennington, New Jersey 08534 (US). ZA, ZM, ZW. BILDER, Donna M.; c/o Bristol-Myers Squibb Company, (84) Designated States (unless otherwise indicated, for every 311 Pennington Rocky Hill Road, Pennington, New Jersey kind of regional protection available): ARIPO (BW, GH, 08534 (US). MENG, Wei; c/o Bristol-Myers Squibb Com- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [Continued on next page] (54) Title: HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR (57) : The present invention provides com- pounds of Foiinula (I): wherein all variables are as defined in the specification, and compositions com- prising any of such novel compounds. These com- pounds are APJ agonists which may be used as medicaments, in particular for treating cardiovascular disorders. N OH (alk) 0 _ 2 001-4 W O 20 17 / 106396 Al (I) WO 2017/106396 Al MIDEDItitiMIRDEZHEMIHIEBRIERUDIMIE TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: Declarations under Rule 4.17: with international search report (Art 21(3)) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267997P | 2015-12-16 | 2015-12-16 | |
| PCT/US2016/066750 WO2017106396A1 (en) | 2015-12-16 | 2016-12-15 | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804674UA true SG11201804674UA (en) | 2018-06-28 |
Family
ID=57708840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804674UA SG11201804674UA (en) | 2015-12-16 | 2016-12-15 | Heteroarylhydroxypyrimidinones as agonists of the apj receptor |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10669261B2 (en) |
| EP (1) | EP3390400B1 (en) |
| JP (1) | JP6948322B2 (en) |
| KR (1) | KR102742744B1 (en) |
| CN (1) | CN108602813B (en) |
| AR (1) | AR107061A1 (en) |
| AU (1) | AU2016372048B2 (en) |
| BR (1) | BR112018012112A2 (en) |
| CA (1) | CA3008630A1 (en) |
| CL (1) | CL2018001621A1 (en) |
| CO (1) | CO2018007221A2 (en) |
| EA (1) | EA036736B1 (en) |
| ES (1) | ES2854733T3 (en) |
| HK (1) | HK1255163A1 (en) |
| IL (1) | IL259947B (en) |
| MX (1) | MX380669B (en) |
| PE (1) | PE20181487A1 (en) |
| SG (1) | SG11201804674UA (en) |
| TW (1) | TW201725203A (en) |
| UY (1) | UY37026A (en) |
| WO (1) | WO2017106396A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12017502158B1 (en) | 2015-06-03 | 2022-04-27 | Bristol Meyers Squibb Co | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| WO2017066402A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| PE20181269A1 (en) | 2015-12-04 | 2018-08-03 | Bristol Myers Squibb Co | APELINE RECEPTOR AGONISTS AND METHODS OF USE |
| MA55064A (en) | 2015-12-16 | 2021-09-29 | Loxo Oncology Inc | COMPOUNDS USED AS KINASE INHIBITORS |
| CN109195963B (en) | 2016-03-24 | 2021-04-23 | 百时美施贵宝公司 | 6-Hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamide as APJ agonist |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| WO2017218617A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| JP7037558B2 (en) | 2016-10-14 | 2022-03-16 | ブリストル－マイヤーズ スクイブ カンパニー | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonist |
| EP3541810B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| MA46827A (en) | 2016-11-16 | 2019-09-25 | Amgen Inc | CYCLOALKYL SUBSTITUTE TRIAZOLE COMPOUNDS AS APJ RECEPTOR AGONISTS |
| MA46824A (en) | 2016-11-16 | 2019-09-25 | Amgen Inc | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS APJ RECEPTOR AGONISTS |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| US6174998B1 (en) | 1996-03-12 | 2001-01-16 | Roche Diagnostics Gmbh | C-nucleoside derivatives and their use in the detection of nucleic acids |
| JPH08311041A (en) | 1995-03-16 | 1996-11-26 | Takeda Chem Ind Ltd | Heterocyclic compound and preparation therefrom |
| CZ298812B6 (en) | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidinedione derivatives, process of their preparation, pharmaceutical compositions in which the derivatives are comprised and their use in the treatment of diabetes mellitus and related diseases |
| US6369067B1 (en) | 1997-10-27 | 2002-04-09 | Dr. Reddy's Research Foundation | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
| KR100781425B1 (en) * | 2000-02-16 | 2007-12-03 | 스미스클라인비이참피이엘시이 | Pyrimidin-4-one Derivatives as LDL-PLA2 Inhibitors |
| JP2004504302A (en) | 2000-07-18 | 2004-02-12 | ニューロジェン・コーポレーション | 5-substituted 2-aryl-4-pyrimidinone |
| WO2002081454A1 (en) | 2001-04-09 | 2002-10-17 | Dr. Reddy's Laboratories Ltd. | Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| KR20050036911A (en) | 2002-05-09 | 2005-04-20 | 싸이토키네틱스, 인코포레이티드 | Compounds, methods and compositions |
| JP2005530806A (en) | 2002-05-23 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | Mitotic kinesin inhibitor |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| EP1620428A1 (en) | 2003-04-23 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Substituted pyrimidinones and pyrimidinthiones as crf antagonists |
| US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1682534A2 (en) | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
| AU2004305069C1 (en) | 2003-12-19 | 2010-07-29 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| JP4517349B2 (en) | 2004-07-28 | 2010-08-04 | 宇部興産株式会社 | Method for producing pyrimidin-4-one compound |
| DE102005025315A1 (en) | 2005-06-02 | 2006-12-14 | Merck Patent Gmbh | Low viscosity ionic liquids |
| WO2007037543A1 (en) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Biarylamide derivative |
| MX2008007049A (en) | 2005-11-30 | 2008-10-23 | Vertex Pharma | Inhibitors of c-met and uses thereof. |
| WO2007124397A2 (en) | 2006-04-21 | 2007-11-01 | Trustees Of Boston University | Ionic viscoelastics and viscoelastic salts |
| WO2008052861A2 (en) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Method for producing 1,3-heteroaromatic carbonates |
| WO2008052863A2 (en) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Method for reacting 1,3-heteroaromatic 2-carboxylates with water |
| MX2009008531A (en) | 2007-02-16 | 2009-08-26 | Amgen Inc | Nitrogen-containing heterocyclyl ketones and methods of use. |
| WO2009152902A2 (en) | 2008-05-28 | 2009-12-23 | Merck Patent Gmbh, | Ionic liquids |
| DE102008031480A1 (en) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Salts containing a Pyrimidincarbonsäure derivative |
| WO2010072696A2 (en) | 2008-12-22 | 2010-07-01 | Basf Se | Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors |
| AR076601A1 (en) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | PYRIMIDINS AS THERAPEUTIC AGENTS |
| US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| US9518068B2 (en) | 2011-05-31 | 2016-12-13 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| JP2014522570A (en) | 2011-05-31 | 2014-09-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Electrolyte compound |
| CN102903954B (en) | 2011-07-25 | 2015-06-03 | 微宏动力系统（湖州）有限公司 | Lithium ion secondary battery containing ion liquid electrolyte |
| DE102012006896A1 (en) | 2012-04-05 | 2013-10-10 | Merck Patent Gmbh | New perfluoroalkyl fluorosilicate salts useful e.g. as solvent or solvent additive, catalyst or phase transfer catalyst, electrolyte component, fluorosurfactant, heat carrier, release agent or extracting agent, plasticizer, and lubricant |
| WO2013184755A2 (en) | 2012-06-07 | 2013-12-12 | Georgia State University Research Foundation, Inc. | Seca inhibitors and methods of making and using thereof |
| KR20150058284A (en) * | 2012-09-21 | 2015-05-28 | 사노피 | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators |
| WO2014056844A1 (en) | 2012-10-10 | 2014-04-17 | Basf Se | Ionic liquids based on oxalic acid mono esters |
| DE102012021452A1 (en) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salts with trihydroperfluoroalkoxybutanesulfonate or trihydroperfluoroalkoxypropanesulfonate anion |
| WO2014078778A2 (en) | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| DE102013016324A1 (en) | 2013-10-04 | 2015-04-09 | Merck Patent Gmbh | Perfluoroalkylfluoro- or Perfluoralkylchlorgermanate |
| WO2015079028A1 (en) | 2013-11-29 | 2015-06-04 | Vtu Holding Gmbh | Method for curing an adhesive using microwave irradiation |
| KR101550846B1 (en) | 2014-01-29 | 2015-09-07 | 한국과학기술연구원 | Single step multi-atom doping method of carbon materials and use thereof |
| KR101531023B1 (en) | 2014-05-27 | 2015-06-23 | 한국과학기술연구원 | Production method of highly strong and conductive carbon nano tube fiber by pyrolysis gas doping and carbon nano tube fiber produced thereby |
| US10570128B2 (en) * | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| MA39999A (en) * | 2014-06-06 | 2015-12-10 | Res Triangle Inst | Apelin receptor (apj) agonists and uses thereof |
| WO2016074757A1 (en) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Method for the preparation of mono- and bis(perfluoroalkyl)fluorophosphate salts and their acids |
| PH12017502158B1 (en) * | 2015-06-03 | 2022-04-27 | Bristol Meyers Squibb Co | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| WO2017066402A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as apj agonists |
| PE20181269A1 (en) | 2015-12-04 | 2018-08-03 | Bristol Myers Squibb Co | APELINE RECEPTOR AGONISTS AND METHODS OF USE |
| CN109195963B (en) | 2016-03-24 | 2021-04-23 | 百时美施贵宝公司 | 6-Hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamide as APJ agonist |
| WO2017218633A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists |
| WO2017218617A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| JP7037558B2 (en) | 2016-10-14 | 2022-03-16 | ブリストル－マイヤーズ スクイブ カンパニー | 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonist |
-
2016
- 2016-12-15 SG SG11201804674UA patent/SG11201804674UA/en unknown
- 2016-12-15 EA EA201891336A patent/EA036736B1/en not_active IP Right Cessation
- 2016-12-15 TW TW105141572A patent/TW201725203A/en unknown
- 2016-12-15 JP JP2018531333A patent/JP6948322B2/en active Active
- 2016-12-15 PE PE2018001129A patent/PE20181487A1/en unknown
- 2016-12-15 CN CN201680081704.3A patent/CN108602813B/en active Active
- 2016-12-15 CA CA3008630A patent/CA3008630A1/en not_active Abandoned
- 2016-12-15 EP EP16820507.8A patent/EP3390400B1/en active Active
- 2016-12-15 MX MX2018007155A patent/MX380669B/en unknown
- 2016-12-15 BR BR112018012112-6A patent/BR112018012112A2/en not_active Application Discontinuation
- 2016-12-15 AR ARP160103867A patent/AR107061A1/en unknown
- 2016-12-15 ES ES16820507T patent/ES2854733T3/en active Active
- 2016-12-15 AU AU2016372048A patent/AU2016372048B2/en not_active Ceased
- 2016-12-15 HK HK18114280.0A patent/HK1255163A1/en unknown
- 2016-12-15 US US16/061,365 patent/US10669261B2/en active Active
- 2016-12-15 UY UY0001037026A patent/UY37026A/en unknown
- 2016-12-15 KR KR1020187019799A patent/KR102742744B1/en active Active
- 2016-12-15 WO PCT/US2016/066750 patent/WO2017106396A1/en not_active Ceased
-
2018
- 2018-06-11 IL IL259947A patent/IL259947B/en active IP Right Grant
- 2018-06-15 CL CL2018001621A patent/CL2018001621A1/en unknown
- 2018-07-11 CO CONC2018/0007221A patent/CO2018007221A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20181487A1 (en) | 2018-09-18 |
| MX380669B (en) | 2025-03-12 |
| AU2016372048B2 (en) | 2021-02-04 |
| HK1255163A1 (en) | 2019-08-09 |
| ES2854733T3 (en) | 2021-09-22 |
| MX2018007155A (en) | 2018-08-15 |
| TW201725203A (en) | 2017-07-16 |
| AU2016372048A1 (en) | 2018-08-02 |
| AR107061A1 (en) | 2018-03-14 |
| KR20180095577A (en) | 2018-08-27 |
| US10669261B2 (en) | 2020-06-02 |
| CA3008630A1 (en) | 2017-06-22 |
| JP2018538304A (en) | 2018-12-27 |
| CL2018001621A1 (en) | 2018-08-03 |
| JP6948322B2 (en) | 2021-10-13 |
| CN108602813A (en) | 2018-09-28 |
| CO2018007221A2 (en) | 2018-07-19 |
| IL259947A (en) | 2018-07-31 |
| CN108602813B (en) | 2021-10-29 |
| WO2017106396A1 (en) | 2017-06-22 |
| UY37026A (en) | 2017-06-30 |
| EA036736B1 (en) | 2020-12-14 |
| EP3390400A1 (en) | 2018-10-24 |
| BR112018012112A2 (en) | 2018-12-04 |
| IL259947B (en) | 2020-10-29 |
| US20180362508A1 (en) | 2018-12-20 |
| KR102742744B1 (en) | 2024-12-12 |
| EP3390400B1 (en) | 2021-01-20 |
| EA201891336A1 (en) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909918XA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201808215SA (en) | Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201901188VA (en) | Metal powder feedstocks for additive manufacturing, and system and methods for producing the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201805955RA (en) | Web-wound rolls with web edge treatment by printable adhesive compositions | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |